FIGS · FIGS, Inc. · Stock research

Current Thesis

Eleven sessions after the 2026-08-06 Q2 print, the re-rating has not given back. That release carried net revenue $196.6M (+28.8% YoY) against $185.855M consensus, diluted EPS $0.15 against $0.07 estimated, FY2026 revenue guidance lifted to $757.318M from a prior $719.452M–$732.074M band, and a repurchase authorization doubled to $200M. The shares closed 2026-08-21 at $14.68, above the $14.26 printed in the first full session after the report.

The narrative leg on offer is durability: a 2021 DTC IPO that flatlined for three years has posted a third consecutive quarter of 25%+ revenue growth in a category — healthcare apparel — whose demand is a replacement cycle rather than a fashion cycle. What remains untested is margin quality. Of 820bp of gross-margin expansion to 75.2%, 780bp was attributed to $7.9M of IEEPA tariff refunds recognized in the quarter, and management flagged higher non-IEEPA tariffs in the same release. No company-scheduled event falls inside the next 30 days; the first clean margin comparison arrives with Q3 (~2026-11-05, est.).

Bullish and bearish views on FIGS, Inc.

The model's bull view on FIGS, Inc. (FIGS), in brief: Q2 2026, reported 2026-08-06: net revenue $196.6M, +28.8% YoY, roughly $10.5M above the $185.855M consensus; diluted EPS $0.15 versus $0.07 estimated; net income $28.4M against $7.1M a year earlier. The bear view: The margin headline that drove the move does not annualize on its own terms. Both cases follow in full.

Bull Case

• Q2 2026, reported 2026-08-06: net revenue $196.6M, +28.8% YoY, roughly $10.5M above the $185.855M consensus; diluted EPS $0.15 versus $0.07 estimated; net income $28.4M against $7.1M a year earlier.
• FY2026 revenue guidance $757.318M versus $729.093M Street; growth outlook to approximately 20% from 14–16%; adjusted EBITDA margin outlook to 14.8–15.0% from 13.0–13.2%; operating margin outlook to approximately 10.8% from 7.8–8.0%.
• Unit economics improved without a promotional giveback: trailing-twelve-month active customers 3.1M (+13.2% YoY), average order value a company-record $127 (+8.5%), revenue per active customer $229 (+10%).
• International was 19% of Q2 sales and grew 67% YoY with served countries expanded from 58 to 85; the U.S., still 81% of sales, grew 22%. Non-scrubwear reached 18% of revenue at +40% YoY.
• Cash generation inflected: H1 2026 free cash flow $38.6M against -$5.6M in the prior-year half; cash, equivalents and short-term investments $296.3M, +24% YoY.
• Sell-side revisions clustered in one session on 2026-08-07, four up and one down: BTIG $20→$22 (Buy), KeyBanc $19→$20 (Overweight), Roth MKM $17→$18 (Buy), Goldman Sachs $14→$16 (Hold), Telsey $17→$16 (Hold). As of 2026-08-22 stockanalysis.com shows a $18.63 average across 9 analysts, high $22, low $15 — the lowest published target sits above the 2026-08-21 close.
• Form 4 filings for July and August 2026 record tax-withholding dispositions only — with no discretionary open-market insider sale filed into post-print strength as of 2026-08-22.
• The buyback was running before it was enlarged: $32.8M repurchased in H1 2026, $24M of it in Q2, then the authorization raised by $100M to $200M on 2026-08-06.

Bear Case

• The margin headline that drove the move does not annualize on its own terms. 780bp of the 820bp expansion came from a $7.9M refund recognition; Q3 is the first period compared without it.
• RSI(14) printed 83.8 at the 2026-08-21 close, up from 81.9 on 2026-08-07 — two weeks of overbought readings with no meaningful reset in between.
• Every piece of incremental company information is now sixteen days old. Nothing company-specific has been dated since the 2026-08-07 analyst actions.
• The shares remain 14.3% below the $17.12 52-week high, and the three-month price change of +17.1% was delivered almost entirely in the single post-print gap.
• Precedent from this year cuts against automatic follow-through: the Q1 2026 print on 2026-05-07 beat and the shares fell.
• Scrubwear was 82% of Q2 revenue. Demand is levered to healthcare headcount and a slowdown there has no offset elsewhere in the mix.
• Short interest at the last available measurement was 17.6M shares, 11.6% of float, up 144.9% since July 2025 (fintel, retrieved 2026-08-09) — a pre-print reading. If the gap was substantially covering, the marginal buyer thins once the short base normalizes.
• Dispersion off identical information: Telsey cut to $16 the same morning BTIG went to $22.

Setup & Price Structure

• Reference close 2026-08-21: $14.68. 52-week high $17.12, leaving the shares 14.3% below it. Three-month price change +17.1%. RSI(14) 83.8.
• The first post-print close was $14.26 on 2026-08-07; a 2026-08-17 close of $14.32 sits inside the subsequent range; 2026-08-21 closed $14.68. The gap has not been filled.
• Structure: an eleven-session shelf roughly between $14.2 and $14.7 sitting on top of an unfilled gap, with no intermediate overhead reference dated between that shelf and the $17.12 52-week high.
• The narrative is accelerating. Dating it — the guidance raise on 2026-08-06, five sell-side target revisions inside one session on 2026-08-07, and eleven sessions through 2026-08-21 in which the gap was held instead of sold. The qualifier is honest: headline flow has been empty since 2026-08-07, and if the 2026-08-26 short-interest publication and the early-September payroll detail pass without adding participants, a well-known story with moderating flow is what maturing would look like in this name.
• Crowding and positioning observables, stated as observables: RSI above 80 on both dated readings; the lowest published target ($15) above the last close; short interest 11.6% of float on the most recent settlement, measured before the print; no equity issuance and instead a doubled repurchase authorization; no discretionary insider sale filed in July or August 2026; no earnings date inside the next 30 days, so nothing company-controlled resolves before mid-October at the earliest.

Catalyst Calendar (next 30 days)

• 2026-08-26 (est.) — FINRA semi-monthly short-interest publication covering the 2026-08-14 settlement date. First measurement of whether the 17.6M-share, 11.6%-of-float short base covered into the gap or was rebuilt at higher prices.
• ~2026-09-04 (est.) — August U.S. employment report, healthcare and ambulatory-services payroll detail. Scrubwear was 82% of Q2 revenue, so healthcare headcount is the end-market driver behind the +13.2% active-customer line.
• ~2026-09-10 (est.) — FINRA publication for the 2026-08-31 settlement date. A single reading after a gap says little; two consecutive readings show direction.
• Outside the window: Q3 2026 results ~2026-11-05 (est.), date not yet announced. The Q2 date was announced 2026-07-16, so a Q3 announcement would be expected around mid-October.

What Would Change Our Mind

The structure carrying the thesis is the unfilled gap between the pre-print zone near $10.92 and the 2026-08-07 close of $14.26, plus the eleven-session shelf built on top of it. Losing that shelf would recast eleven sessions of absorption as distribution: a weekly close below $13.00 gives back the bulk of the post-print re-rating and puts the gap back in play.

Fundamentally, any reduction to the $757.318M FY2026 revenue guide or to the 14.8–15.0% adjusted EBITDA margin outlook at the Q3 print (~2026-11-05, est.) breaks the re-acceleration leg directly, as would a Q3 gross margin materially below 75.2% attributed to the absence of the $7.9M IEEPA refund with no offset in the product-cost line.

On positioning: short interest falling sharply from 17.6M shares across the 2026-08-26 and ~2026-09-10 publications while the shares simultaneously fail to hold the post-print shelf would date the August move as covering rather than new demand.

The confirming evidence runs the other way: a close above the $17.12 52-week high, or a short-interest series that holds near 11.6% of float while price grinds higher, would say the bid is incremental long demand and the shelf is a launch point rather than a distribution zone.

Correlation Notes

• This is not an AI-complex name. The relevant betas are consumer discretionary and U.S. healthcare labor. Healthcare and social assistance has been the dominant American payroll-add category; because active customers is a trailing-twelve-month measure, the reported customer line lags any inflection in that series in both directions.
• Trade policy is a direct P&L input here, not background noise: the $7.9M IEEPA refund landed inside reported gross margin, so tariff headlines translate to the margin line in a way they do not for a domestically sourced apparel peer.
• With short interest at 11.6% of float, the shares trade with the small-cap short-covering cohort on strong tape days, and that linkage is loosest in the sessions immediately following a FINRA publication.
• There is no listed pure-play scrubwear comparable, so read-across pricing comes from broader DTC apparel prints and from the healthcare-staffing complex rather than from a direct peer.